Stock Market News
Scancell announces collaboration with ISA Pharmaceutical
Scancell Holdings announced on Thursday that it has entered a collaboration agreement with Dutch company ISA Pharmaceutical, which will see further development of Scancell's Moditope anti-cancer platform.
In return for an upfront payment and royalty fees, the agreement will allow Scancell an exclusive worldwide license to use ISA's AMPLIVANT technology to manufacture, develop and commercialise its Moditope development candidate, Modi-1.
Cliff Holloway, chief executive of Scancell, said: "This collaboration with ISA Pharmaceuticals is an important step in the continued development and commercialisation of our first Moditope immunotherapy, Modi-1, which has the potential to treat patients with triple negative breast cancer, ovarian cancer and sarcoma who are resistant to other immunotherapies."
Previous pre-clinical data indicated that conjugation of the Modi-1 peptides to AMPLIVANT enhanced anti-tumour responses and tumour eradication, including protection against tumour re-challenge.
Founded in 1997 as a spin-out from the University of Nottingham, Scancell develops products that stimulate the immune system to treat or prevent cancer and has previously agreed a Moditope collaboration with German firm BioNTech.
"We believe that combining Modi-1 with an enabling adjuvant technology such as AMPLIVANT has the potential to significantly enhance its efficacy in patients and we are looking forward to moving this important and novel therapy into the clinic in the first half of 2019," said Holloway.
As of 1405 GMT, Scancell's shares were up 10.8% to 13.85p.
In return for an upfront payment and royalty fees, the agreement will allow Scancell an exclusive worldwide license to use ISA's AMPLIVANT technology to manufacture, develop and commercialise its Moditope development candidate, Modi-1.
Cliff Holloway, chief executive of Scancell, said: "This collaboration with ISA Pharmaceuticals is an important step in the continued development and commercialisation of our first Moditope immunotherapy, Modi-1, which has the potential to treat patients with triple negative breast cancer, ovarian cancer and sarcoma who are resistant to other immunotherapies."
Previous pre-clinical data indicated that conjugation of the Modi-1 peptides to AMPLIVANT enhanced anti-tumour responses and tumour eradication, including protection against tumour re-challenge.
Founded in 1997 as a spin-out from the University of Nottingham, Scancell develops products that stimulate the immune system to treat or prevent cancer and has previously agreed a Moditope collaboration with German firm BioNTech.
"We believe that combining Modi-1 with an enabling adjuvant technology such as AMPLIVANT has the potential to significantly enhance its efficacy in patients and we are looking forward to moving this important and novel therapy into the clinic in the first half of 2019," said Holloway.
As of 1405 GMT, Scancell's shares were up 10.8% to 13.85p.
Related share prices |
---|
Scancell Holdings (SCLP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price